mercredi 25 avril 2018

Onco Actu du 25 avril 2018

1. Biologie

Study reveals subtypes of lymphoma [NIH]

3.1.1 Prévention - Tabac - e-cigs

F.D.A. Cracks Down on Sales of E-Cigarettes to Minors [NY Times]

E-Cigarette Sting Operation Prompts U.S. Warnings to Retailers [Bloomberg]

Statement from FDA Commissioner Scott Gottlieb, M.D., on new enforcement actions and a Youth Tobacco Prevention Plan to stop youth use of, and access to, JUUL and other e-cigarettes [FDA]

4.2 Dép., diag. & prono. - Génome

Broad Institute to sequence its 100,000th whole human genome on National DNA Day [Broad Institute]

5.10 Traitements - Essais

U.K. commits to EU trial rules post-Brexit as CRUK hails ‘fantastic news’ [FierceBiotech]

5.12.1 Immunothérapies - partenariats

Shire-hunting Takeda notches R&D collaboration with Nektar, pair to combo I-O drugs [FierceBiotech]

5.12.3 Immunothérapies-combinaisons

It's another fail for AstraZeneca's I-O combo, but it may not mean what you think [FiercePharma]

EU reviewing MSD’s Keytruda/chemo combo [PharmaTimes]

AstraZeneca flop a fresh blow to cancer immunotherapy combination [Reuters]

5.12.8 Immunothérapies - Economie

How Blueprint Medicines Got The Blues [Forbes]

5.2 Pharma

Revolution Medicines tees up for oncology IND with $56M series B [FierceBiotech]

FDA slaps partial hold on Epizyme’s lead drug; analysts say ‘don’t panic’ [FierceBiotech]

Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer [Xconomy]

5.2.2 Pharma - Fusions & Acquisitions

Fifth and final bid? A determined Takeda said to be nearing $60B-plus Shire deal [FiercePharma]

Takeda reaches preliminary deal to buy Shire for close to $65B [EndPoints]

5.2.3 Pharma - économie

Is Biopharma Investing Too Much In Cancer R&D? [Forbes]

Celldex to ax 20% of staff after midstage glembatumumab rout [FierceBiotech]

In a blow for pharma, Supreme Court upholds the hated IPR patent challenge [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

Rent increase hits Europe’s drug regulator before Brexit move [Nature]

The European Medicines Agency and the Netherlands agree on Seat Agreement [EMA]

5.9 AACR

A cancer drug tailored to your tumor? Experts trade barbs over ‘precision oncology’ [Science]

6. Lutte contre les cancers

Reuters Top 100: Europe's Most Innovative Universities – 2018 [Reuters]

How a New Kind of Autopsy Is Helping in the Fight Against Cancer [Time]

Scientists’ early grant success fuels further funding [Nature]

6.10 Politiques

Windrush scandal: Albert Thompson gets cancer treatment date [The Guardian]